Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Part of paid clinical trials in Chapel Hill, North Carolina.

Sponsor
UNC Lineberger Comprehensive Cancer Center
Study ID
NCT00246753
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • lapatinib ditosylate — DRUG
    1500 mg, daily until disease progression

Study Details

RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did not respond to hormone therapy.

Key Dates

Start date
Oct 31, 2005
Status verified
May 2017
Primary completion
Jul 31, 2012
Completion
May 31, 2013

Study Design

Enrollment
29 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Single Arm Trial
    Single Arm Trial where each patient receives GW572016 (lapatinib ditosylate) at a dose of 1500mg daily initially until disease progression or unacceptable toxicity.

Primary Outcome Measure

Number of Patients Experiencing Decline in Prostate-specific Antigen [ Time Frame: 4 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel HillChapel HillNorth Carolina27599-7295-
Duke Comprehensive Cancer CenterDurhamNorth Carolina27710-
Rex Cancer Center at Rex HospitalRaleighNorth Carolina27607-

Find similar trials in Chapel Hill, NC

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill· Chapel Hill, NCDuke Comprehensive Cancer Center· Durham, NCRex Cancer Center at Rex Hospital· Raleigh, NC

Related Studies